toxylact: a04ab57 chlorphenoxamine combinations
The first professional lActological database in the word
Chlorphenoxamine combinations (ATC A04AB57) are oral sedating antihistamine‑containing antiemetic products, used mainly for pruritus, motion sickness and antiparkinsonian indications, with relevant cautions in breastfeeding due to anticholinergic and sedative effects.medpedia.framar+6
ATC class overview
ATC A04AB57 belongs to the group of
antiemetics and drugs against
nausea (A04), within the subgroup of antihistamines used as
vestibular
suppressants and antiemetics (A04AB).^atcddd.fhi+2
Products in this class contain chlorphenoxamine in fixed
combinations with
other active substances (for example, sympathomimetics or
other antiemetics),
formulated for systemic, usually oral, use.drugs.ncats+3
Active substance and pharmacological profile
Chlorphenoxamine is a first‑generation
ethanolamine‑class
antihistamine, structurally related to diphenhydramine and
acting as a
histamine H1‑receptor antagonist.drugbank+4
It also has significant anticholinergic and sedative
properties, which account
for its antipruritic, antiemetic/anti‑motion‑sickness and
antiparkinsonian uses.wikipedia+5
Therapeutic indications
In combinations classified as A04AB57,
chlorphenoxamine is used
to prevent and treat nausea and vomiting, particularly
related to motion
sickness or vestibular disorders.synapse.patsnap+3
Outside the antiemetic indication, it is employed as an
antipruritic in
allergic skin conditions and as an adjunct in Parkinson’s
disease due to its
central anticholinergic effect.build.openmodelica+4
Dosage, administration and legal status
A04AB57 chlorphenoxamine combinations are
administered orally,
with dose and regimen individualized according to age,
indication, and the
other components in the combination product.medpedia.framar+3
These medicines are prescription‑only (Rx), and initiation
or dose adjustment
should be performed by a physician familiar with the
patient’s comorbidities
and concomitant therapy.drugs.ncats+1
Adverse effects and toxicological considerations
Typical dose‑related adverse reactions include
drowsiness, fatigue,
dizziness and general weakness, reflecting central
H1‑blockade and
anticholinergic activity.drugbank+5
At higher exposures or in susceptible patients (elderly,
those with CNS disease
or polypharmacy), anticholinergic toxicity may manifest with
confusion,
agitation, blurred vision, tachycardia, urinary retention
and, rarely, delirium
or seizures.onlinelibrary.wiley+5
Contraindications and precautions
Use is contraindicated in individuals with
known hypersensitivity
to chlorphenoxamine or any component of the combination
product.build.openmodelica+3
Caution is required in glaucoma, prostatic hypertrophy,
urinary retention,
cardiovascular disease, epilepsy, and in patients receiving
other sedatives,
anticholinergics or sympathomimetics, because of additive
CNS and autonomic
effects.synapse.patsnap+4
Lactation: exposure and potential risks
Like other sedating first‑generation
antihistamines,
chlorphenoxamine is expected to pass into breast milk in low
amounts, but
robust lactation pharmacokinetic data are lacking.nhs+3
Experience with related sedating H1‑antagonists (for example
chlorphenamine)
suggests that infant exposure is usually below a relative
infant dose of 5%,
yet sedation, poor feeding and, theoretically, reduced milk
production may
occur, particularly in neonates and young infants.theconversation+3
Lactation risk classification and clinical recommendations
On the basis of class data for sedating
antihistamines and their
known pharmacology, chlorphenoxamine‑containing combinations
can be considered
“compatible with breastfeeding with caution,” with
preference for short‑term,
lowest‑effective doses and close infant monitoring.healthdirect+3
Non‑sedating antihistamines (such as cetirizine or
loratadine) are generally
preferred for allergy in breastfeeding women, and
non‑anticholinergic
antiemetic strategies should be considered first line,
reserving A04AB57 combinations
for situations where benefits clearly outweigh potential
risks to the infant
and lactation.sps+4
Practical lactological guidance
If chlorphenoxamine combinations are used
during breastfeeding,
clinicians should monitor the breastfed child for excessive
sleepiness, feeding
difficulties, poor weight gain or unusual behavioral
changes, and reassess
therapy promptly if such signs appear.sps+4
Mothers should be advised to avoid prolonged, continuous
use; schedule doses
immediately after breastfeeding or before the infant’s
longest sleep; and avoid
co‑administration of other sedating drugs or decongestants
that can further
suppress prolactin and milk supply.theconversation+5



